TorS - Reframing a rational for type 2 diabetes treatment

Area of Science:

• Biomedical Science
• Metabolic Disease Research
• Molecular Medicine

Background:

• Hyperactivity of the mammalian target of rapamycin complex 1 (mTORC1) is implicated in various pathologies.
• A cohesive disease entity, termed Tors (mammalian target of rapamycin complex 1 syndrome), is proposed, driven by mTORC1 dysregulation.

Purpose of the Study:

• To introduce and define the Tors paradigm.
• To explore the potential of the Tors paradigm in explaining current treatment outcomes.
• To suggest the Tors paradigm's utility in developing new therapeutic approaches.

Main Methods:

• Conceptual framework development.
• Literature review and synthesis of existing research on mTORC1 and associated diseases.
• Analysis of treatment efficacy in the context of the proposed Tors paradigm.

Main Results:

• The Tors paradigm encompasses a wide range of diseases including obesity, type 2 diabetic hyperglycemia, cardiovascular diseases, non-alcoholic fatty liver disease, certain cancers, and neurodegeneration.
• The paradigm offers a potential explanation for why standard treatments for type 2 diabetes (T2D) alleviate both glycaemic and non-glycaemic manifestations of Tors.
• The Tors paradigm may serve as a foundation for discovering innovative treatments targeting mTORC1 hyperactivity.

Conclusions:

• The Tors paradigm provides a unifying framework for understanding a spectrum of diseases linked to mTORC1.
• This paradigm has implications for the efficacy of existing therapies and the development of future treatments for metabolic and other related disorders.